BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 14, 2026
Home » Authors » Omar Ford

Omar Ford

Articles

ARTICLES

Direct Flow Medical gains patient expansion approval in SALUS trial

April 13, 2015
By Omar Ford
Direct Flow Medical (Santa Rosa, California) said it has received FDA approval to broaden its SALUS trial including the addition of high risk patients and randomization against Medtronic's (Dublin) CoreValve.
Read More

MDD's Diagnostics Extra

April 10, 2015
By Omar Ford

Cadence Biomedical secures key distribution agreements for Kickstart

April 10, 2015
By Omar Ford

Financings: Funding surge down from last year; IPO enthusiasm seems to be thinning

April 9, 2015
By Omar Ford

Medtronic strengthens its diabetes market with collaboration, investment

April 9, 2015
By Omar Ford
In a move to strengthen its position in the diabetes market, Medtronic (Dublin) has formed an agreement with DreaMed Diabetes (Petah Tikvah, Israel), for the development and marketing of products incorporating DreaMed's MD-Logic Artificial Pancreas algorithm in the med-tech giant's insulin pumps.
Read More

SEMDA 2015: Clemson researchers look to revolutionize shoulder surgery

April 7, 2015
By Omar Ford

Immunexpress vying for FDA clearance of its sepsis test

April 6, 2015
By Omar Ford
When it comes right down to detecting sepsis most diagnostics companies use methods to identify the pathogen. But therein lies the issue with looking for the pathogen, because it has to be in the blood sample or the fluid sample to start with, otherwise a clinician can't find it. In the clinician's world this causes a lot of false negatives, because if that pathogen is not in that sample or that blood sample, it doesn't matter how fast or sensitive that technology is, the clinician won't find it."
Read More

SGR spectre haunted AAOS 2015 conference

April 3, 2015
By Omar Ford
The Las Vegas casinos were teeming with activity last week, but the true bets from orthopedic surgeons who descended upon sin city during the American Academy of Orthopedic Surgeons (AAOS) weren’t originating from the tables in their hotel lobbies. True bets were being placed on what would happen regarding the Sustainable Growth Rate (SGR). Ultimately the House would overwhelmingly pass the bill. But the Senate went into recess before making a final vote. For the uninitiated, in 1997, Congress adopted the SGR formula as part of the Balanced Budget Act. The idea was to control federal health care spending. The...
Read More

MDD's Diagnostics Extra

April 3, 2015
By Omar Ford

SEMDA 2015: Device firms, hospitals could see roles changing due to data integration

April 3, 2015
By Omar Ford
ATLANTA — Could Google (Mountain View, California) be a strong enough healthcare company to overtake med-tech giant Medtronic (Dublin, Ireland) one day? While it might seem impossible now, under the premise of integrated healthcare, a lot of unlikely players that have technologies to track data could in fact have leading market share in the healthcare industry.
Read More
View All Articles by Omar Ford

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing